587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models

• John Williams,
• Wilson Guzman,
• Minjie Zhang,
• Parker Johnson,
• Megan McLaughlin,
• Kurt Jenkins,
• Caitlin O’Toole,
• Magali Pederzoli-Ribeil,
• Margaret Karow,
• Ronan O’Hagan,
• Jennifer O’Neil,
• Ugur Eskiocak,
• Miso Park,
• Timothy Clackson

Affiliations

John Williams

2Beckman Research Institute, City of Hope, Duarte, CA, USA

Wilson Guzman

Aff168 grid.467308.e0000 0004 0412 6436EMD Serono Billerica MA USA

Minjie Zhang

Xilio Therapeutics, Waltham, MA, USA

Parker Johnson

Xilio Therapeutics, Waltham, MA, USA

Megan McLaughlin

Xilio Therapeutics, Waltham, MA, USA

Kurt Jenkins

Xilio Therapeutics, Waltham, MA, USA

Caitlin O’Toole

Xilio Therapeutics, Waltham, MA, USA

Magali Pederzoli-Ribeil

Xilio Therapeutics, Waltham, MA, USA

Margaret Karow

Xilio Therapeutics, Waltham, MA, USA

Ronan O’Hagan

Xilio Therapeutics, Waltham, MA, USA

Jennifer O’Neil

Xilio Therapeutics, Waltham, MA, USA

Ugur Eskiocak

Xilio Therapeutics, Waltham, MA, USA

Miso Park

2Beckman Research Institute, City of Hope, Duarte, CA, USA

Timothy Clackson

1Xilio Therapeutics, Waltham, MA, USA